Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$18.31 -2.9%	$15.87	$9.57 ▼ $30.41	$2.53B	0.93	1.57 million shs	1.45 million shs
GMTX Gemini Therapeutics	$56.91 -1.9%	$49.90	$1.16 ▼ $14.10	$2.47B	-0.12	189,291 shs	275,330 shs
IBRX ImmunityBio	$2.81 -2.1%	$2.71	$1.83 ▼ $7.48	$2.48B	0.08	6.26 million shs	6.02 million shs
RLAY Relay Therapeutics	$3.60 -3.5%	$3.22	$1.78 ▼ $10.72	$617.22M	1.62	2.08 million shs	1.03 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	0.00%	+9.12%	+16.33%	+48.38%	-34.86%
GMTX Gemini Therapeutics	0.00%	+3.95%	+7.97%	+46.94%	+20.65%
IBRX ImmunityBio	0.00%	+4.07%	-8.47%	-2.77%	-57.55%
RLAY Relay Therapeutics	0.00%	-0.55%	+11.80%	+40.08%	-56.31%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.5857 of 5 stars	3.4	2.0	0.0	3.4	2.1	1.7	0.0
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IBRX ImmunityBio	2.3636 of 5 stars	3.6	1.0	0.0	0.0	3.0	1.7	0.6
RLAY Relay Therapeutics	2.3335 of 5 stars	3.4	1.0	0.0	0.0	2.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.75	Moderate Buy	$43.71	138.75% Upside
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
IBRX ImmunityBio	3.20	Buy	$12.25	335.94% Upside
RLAY Relay Therapeutics	2.83	Moderate Buy	$17.67	390.74% Upside

Current Analyst Ratings Breakdown

Latest RLAY, IBRX, GMTX, and ARWR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/4/2025	IBRX ImmunityBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/3/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/28/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/20/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/20/2025	IBRX ImmunityBio	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$4.25 ➝ $5.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$21.00 ➝ $17.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
5/12/2025	IBRX ImmunityBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
5/12/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/7/2025	RLAY Relay Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $10.00

(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$545.21M	4.64	N/A	N/A	$1.54 per share	11.89
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
IBRX ImmunityBio	$31.22M	79.44	N/A	N/A	($0.57) per share	-4.93
RLAY Relay Therapeutics	$10.01M	61.66	N/A	N/A	$4.65 per share	0.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	21.53	N/A	-45.33%	-12.49%	8/6/2025 (Estimated)
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
IBRX ImmunityBio	-$413.56M	-$0.58	N/A	N/A	N/A	-1,310.30%	N/A	-121.88%	8/11/2025 (Estimated)
RLAY Relay Therapeutics	-$337.71M	-$2.23	N/A	N/A	N/A	N/A	-44.17%	-39.53%	8/5/2025 (Estimated)

Latest RLAY, IBRX, GMTX, and ARWR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	IBRX ImmunityBio	-$0.10	N/A	N/A	N/A	$21.95 million	N/A
8/5/2025	Q2 2025	RLAY Relay Therapeutics	-$0.49	N/A	N/A	N/A	$0.07 million	N/A
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/12/2025	Q1 2025	IBRX ImmunityBio	-$0.12	-$0.15	-$0.03	-$0.15	$17.50 million	$16.52 million
5/5/2025	Q1 2025	RLAY Relay Therapeutics	-$0.50	-$0.46	+$0.04	-$0.46	$0.01 million	$7.68 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	0.31	5.15	5.15
GMTX Gemini Therapeutics	N/A	71.49	71.49
IBRX ImmunityBio	N/A	2.22	2.05
RLAY Relay Therapeutics	N/A	19.96	19.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
GMTX Gemini Therapeutics	75.42%
IBRX ImmunityBio	8.58%
RLAY Relay Therapeutics	96.98%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
GMTX Gemini Therapeutics	12.90%
IBRX ImmunityBio	76.79%
RLAY Relay Therapeutics	4.32%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	132.16 million	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
IBRX ImmunityBio	590	882.62 million	204.86 million	Optionable
RLAY Relay Therapeutics	330	171.45 million	164.04 million	Optionable

RLAY, IBRX, GMTX, and ARWR Headlines

Recent News About These Companies

Relay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sanjiv Patel Sells 61,379 Shares

July 11 at 6:42 AM | insidertrades.com

Sanjiv Patel Sells 61,379 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock

July 10, 2025 | marketbeat.com

Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives $17.67 Consensus PT from Brokerages

July 8, 2025 | americanbankingnews.com

Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Consensus Recommendation of "Moderate Buy" by Brokerages

July 5, 2025 | marketbeat.com

Relay Therapeutics, Inc. (RLAY) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

BofA Reiterates a Buy Rating on Relay Therapeutics (RLAY), Sets a $17 PT

June 24, 2025 | insidermonkey.com

Relay Therapeutics (NASDAQ:RLAY) Stock Price Down 4.9% - Time to Sell?

June 20, 2025 | marketbeat.com

Relay Therapeutics (NASDAQ:RLAY) Stock Price Up 5.7% - Here's What Happened

June 18, 2025 | marketbeat.com

Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

June 11, 2025 | globenewswire.com

Relay Therapeutics’ RLY-2608 Shows Promising 11-Month PFS in Breast Cancer

June 2, 2025 | msn.com

Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025

June 2, 2025 | globenewswire.com

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

May 29, 2025 | globenewswire.com

Relay Therapeutics’ SWOT analysis: ai-driven biotech stock faces pivotal year

May 29, 2025 | investing.com

What Makes Relay Therapeutics (RLAY) a New Buy Stock

May 23, 2025 | zacks.com

Analysts Are Bullish on These Healthcare Stocks: Relay Therapeutics (RLAY), Zura Bio (ZURA)

May 15, 2025 | theglobeandmail.com

Relay Therapeutics, Inc. (RLAY): One of the Best Low Priced Biotech Stocks to Buy Now

May 13, 2025 | insidermonkey.com

Relay Therapeutics Extends Cash Runway into 2029 Amid Clinical Trial Advancements

May 7, 2025 | nasdaq.com

Relay Therapeutics, Inc. (RLAY): A Bull Case Theory

May 7, 2025 | insidermonkey.com

Relay Therapeutics, Inc.: Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates

May 6, 2025 | finanznachrichten.de

Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates

May 5, 2025 | globenewswire.com

Relay Therapeutics Q1 2025 Earnings Preview

May 3, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLAY, IBRX, GMTX, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$18.31 -0.55 (-2.92%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$18.27 -0.04 (-0.22%)

As of 07/11/2025 07:54 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Gemini Therapeutics NASDAQ:GMTX

$56.91 -1.09 (-1.88%)

As of 07/11/2025

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

ImmunityBio NASDAQ:IBRX

$2.81 -0.06 (-2.09%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$2.82 +0.00 (+0.18%)

As of 05:42 AM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Relay Therapeutics NASDAQ:RLAY

$3.60 -0.13 (-3.49%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$3.59 -0.01 (-0.31%)

As of 04:00 AM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time